Rayna B. Rodriguez

Array ( [id] => 20554006 [patent_doc_number] => 20260053786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-26 [patent_title] => FORMULATIONS OF RADIPRODIL [patent_app_type] => utility [patent_app_number] => 19/376486 [patent_app_country] => US [patent_app_date] => 2025-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4581 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19376486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20458210 [patent_doc_number] => 20260007630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-08 [patent_title] => COMPOSITIONS COMPRISING SELECTIVE ANDROGEN RECEPTOR MODULATOR COMPOUNDS IN COMBINATION WITH WEIGHT LOSS DRUGS AND USES THEREOF FOR QUALITY WEIGHT LOSS [patent_app_type] => utility [patent_app_number] => 19/319108 [patent_app_country] => US [patent_app_date] => 2025-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19319108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20555326 [patent_doc_number] => 20260055106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-26 [patent_title] => PARG INHIBITORY COMPOUND [patent_app_type] => utility [patent_app_number] => 19/312178 [patent_app_country] => US [patent_app_date] => 2025-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19312178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20598946 [patent_doc_number] => 20260076949 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-19 [patent_title] => STABLE MONOHYDRATE OF DF2755A AND PROCESS FOR ITS PREPARATION [patent_app_type] => utility [patent_app_number] => 19/288001 [patent_app_country] => US [patent_app_date] => 2025-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19288001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20246776 [patent_doc_number] => 20250295645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-25 [patent_title] => BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS-CLOVES SYNDROME) [patent_app_type] => utility [patent_app_number] => 19/227991 [patent_app_country] => US [patent_app_date] => 2025-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1044 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19227991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20307915 [patent_doc_number] => 20250325544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-23 [patent_title] => CDK INHIBITORS [patent_app_type] => utility [patent_app_number] => 19/210825 [patent_app_country] => US [patent_app_date] => 2025-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19210825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20206251 [patent_doc_number] => 20250275971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-04 [patent_title] => CDK INHIBITORS [patent_app_type] => utility [patent_app_number] => 19/210611 [patent_app_country] => US [patent_app_date] => 2025-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19210611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20206252 [patent_doc_number] => 20250275972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-04 [patent_title] => CDK INHIBITORS [patent_app_type] => utility [patent_app_number] => 19/210983 [patent_app_country] => US [patent_app_date] => 2025-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8830 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19210983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20335271 [patent_doc_number] => 20250339391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => METHODS FOR EFFECTIVE MANAGEMENT OF PAIN [patent_app_type] => utility [patent_app_number] => 19/181999 [patent_app_country] => US [patent_app_date] => 2025-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25907 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19181999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20134854 [patent_doc_number] => 20250241898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-31 [patent_title] => Topical Benzimidazole Formulations and Methods for Use in Treating Inflammatory Dermatoses [patent_app_type] => utility [patent_app_number] => 19/180752 [patent_app_country] => US [patent_app_date] => 2025-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19180752 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19846732 [patent_doc_number] => 20250092083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => STEROL BASED IONIZABLE LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 18/907013 [patent_app_country] => US [patent_app_date] => 2024-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18907013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19745552 [patent_doc_number] => 20250034117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => Deuterated 1,3 Dihydro -2H-indole-2-one derivatives [patent_app_type] => utility [patent_app_number] => 18/771709 [patent_app_country] => US [patent_app_date] => 2024-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12485 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18771709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556401 [patent_doc_number] => 20240368193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => KRAS INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/621388 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55725 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 613 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19651235 [patent_doc_number] => 12173003 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-24 [patent_title] => Pyrrolo[3,2-C][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/586070 [patent_app_country] => US [patent_app_date] => 2024-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9777 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 352 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18586070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667482 [patent_doc_number] => 12180209 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-31 [patent_title] => Pyrrolo[3,2-c][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/586021 [patent_app_country] => US [patent_app_date] => 2024-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9777 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18586021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389315 [patent_doc_number] => 20240279185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/433196 [patent_app_country] => US [patent_app_date] => 2024-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20752 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 222 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18433196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19331280 [patent_doc_number] => 20240245710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => Combination Therapy For Prostate Cancer [patent_app_type] => utility [patent_app_number] => 18/429778 [patent_app_country] => US [patent_app_date] => 2024-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9551 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18429778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19311528 [patent_doc_number] => 12037331 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-07-16 [patent_title] => 1-Cyclopropyl-6-fluoro-7-4((5-(4-methoxybenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2h)-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory and anticancer compound [patent_app_type] => utility [patent_app_number] => 18/430134 [patent_app_country] => US [patent_app_date] => 2024-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 4271 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18430134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19624071 [patent_doc_number] => 12162875 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-10 [patent_title] => 1-cyclopropyl-6-fluoro-7-(4-((5(4-methoxybenzylideneamino-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory and anticancer compound [patent_app_type] => utility [patent_app_number] => 18/430131 [patent_app_country] => US [patent_app_date] => 2024-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4238 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18430131 [rel_patent_id] =>[rel_patent_doc_number] =>)